Latest Headlines from Nourish | The Nourish Mission

UK approves second GLP-1 pill for weight loss

What's happened

UK pharmacies are now able to offer orforglipron (Foundayo), the second GLP-1 pill for weight loss, following MHRA approval. The pill, manufactured by Eli Lilly, is available initially by private prescription while NICE assesses a potential NHS rollout in England. It targets BMI thresholds (30+, or 27-30 with weight-related conditions) and is taken daily with no food or water restrictions.

What's behind the headline?

Analysis

  • The move expands access to oral weight-loss treatment, potentially reducing demand on injectables and broadening eligibility. But this raises concerns about counterfeit versions and unregulated sales, which regulators are combating.
  • The policy appears to hinge on ongoing NICE assessment for NHS funding, signaling a two-track pathway: private availability now, NHS integration later.
  • Public health implications include potential improvements in BMI and type 2 diabetes metrics, contingent on safe, regulated access and patient adherence.

Forecast: NICE evaluation will influence the speed and scale of NHS rollout. If funded, expect increased pharmacy-based distribution and standardized patient education to counter counterfeit risk.

How we got here

The MHRA approved the first GLP-1 pill for weight loss in June, following earlier European approvals. Foundayo’s rollout comes as part of ongoing expansion of pharmacological weight-management options in the UK, with suppliers emphasizing safer access through regulated channels.

Our analysis

The Independent reports the pill is approved by the MHRA, with NICE assessing NHS rollout; The Guardian highlights counterfeit concerns and regulatory actions; Both note that Foundayo is the second GLP-1 pill after Wegovy and that the UK is the first European country to approve it.

Go deeper

  • Will NICE approve NHS funding for Foundayo in England?
  • How will pharmacies ensure safe access and prevent counterfeit versions?
  • What are the BMI thresholds for eligibility and how many patients could be affected?

More on these topics


Latest Headlines from Nourish | The Nourish Mission